Source comparison
Melanotan-1 vs. UV Exposure vs. Melanotan-2: Pigmentation Mechanism Comparison
Receptor Target MC1-R selective agonist Indirect activation via p53 stress response and POMC cleavage MC1-R, MC3-R, MC4-R, MC5-R non-selective agonist Melanotan-1's MC1-R selectivity avoids systemic melanocortin effects that cause nausea, appetite suppression,
This comparison does not assign a generated winner or score.
- Receptor Target
- MC1-R selective agonist
- Indirect activation via p53 stress response and POMC cleavage
- MC1-R, MC3-R, MC4-R, MC5-R non-selective agonist
- Melanotan-1's MC1-R selectivity avoids systemic melanocortin effects that cause nausea, appetite suppression, and erectile changes seen with MT-II cross-reactivity
- DNA Damage
- No thymine dimer formation, no CPD accumulation
- Direct CPD formation, oxidative base damage, strand breaks
- No direct DNA damage from peptide itself
- UV tanning and photoprotection are mechanistically incompatible. Melanotan-1 separates pigmentation from carcinogenic photodamage
- Onset to Visible Pigmentation
- 48–72 hours at clinical doses (0.16 mg/kg SC)
- 72–96 hours post-exposure (delayed tanning phase)
- 24–48 hours at research doses (0.5–1.0 mg SC)
- MT-II's faster onset reflects higher potency but comes with worse side effect profile; clinical trials favor Melanotan-1 for sustained use
- Melanin Type Induced
- Eumelanin-dominant (brown-black polymer)
- Mixed eumelanin and pheomelanin
- Eumelanin-dominant
- Pheomelanin (produced during UV exposure in fair-skinned individuals) offers minimal photoprotection and may generate carcinogenic free radicals under continued UV exposure
- Systemic Side Effects
- Nausea (15–20%), headache, flushing
- Immunosuppression, photoaging, basal/squamous cell carcinoma risk
- Nausea (50–70%), spontaneous erections, hypertension, appetite suppression
- The 3.5× higher nausea rate with MT-II is dose-limiting in most research contexts. Melanotan-1 is better tolerated across multi-week protocols
- Regulatory Status (2026)
- FDA-approved (Scenesse for EPP)
- No regulation
- Not approved for human use (research compound only)
- Melanotan-1 is the only melanocortin peptide with formal approval; MT-II remains an investigational compound despite widespread non-clinical use